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Ribosomal proteins (RP) regulate specific gene expression by selectively translating
subsets of mRNAs. Indeed, in Diamond-Blackfan anemia and 5q– syndrome, mutations in
RP genes lead to a specific defect in erythroid gene translation and cause anemia. Little is
known about the molecular mechanisms of selective mRNA translation and involvement of
ribosomal-associated factors in this process. Ribonuclease inhibitor 1 (RNH1) is a
ubiquitously expressed protein that binds to and inhibits pancreatic-type ribonucleases.
Here, we report that RNH1 binds to ribosomes and regulates erythropoiesis by controlling
translation of the erythroid transcription factor GATA1. Rnh1-deficient mice die between
embryonic days E8.5 and E10 due to impaired production of mature erythroid cells from
progenitor cells. In Rnh1-deficient embryos, mRNA levels of Gata1 are normal, but GATA1
protein levels are decreased. At the molecular level, we found that RNH1 binds to the 40S
subunit of ribosomes and facilitates polysome formation on Gata1 mRNA to confer
transcript-specific translation. Further, RNH1 knockdown in human CD34+ progenitor cells
decreased erythroid differentiation without affecting myelopoiesis. Our results reveal an
unsuspected role for RNH1 in the control of GATA1 mRNA translation and erythropoiesis.
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Introduction
Regulation of gene expression is important for normal develop-
ment. Recent studies show that ribosomal proteins (RPs) regulate 
gene expression by selectively facilitating translation of specific 
mRNAs (1, 2). For example, RPL38 specifically enhances transla-
tion of a subset of Hox mRNAs (3). Mutations in RPs impair ribo-
some function and cause macrocytic anemia in Diamond-Blackfan 
anemia (DBA), a congenital BM failure syndrome, and in 5q– 
syndrome, a subtype of myelodysplastic syndrome (4). Surprising-
ly, the majority of clinical symptoms are related to erythropoiesis. 
In support of these observations, ribosomal deficiencies in DBA 
impair translation of transcripts essential for erythroid differenti-
ation (5, 6). How RPs regulate specific gene expression and how 
mutations in RPs lead to tissue-specific phenotypes are areas of 
active investigation.
Ribonuclease inhibitor 1 (RNH1, also known as RI) is a ubiqui-
tously expressed 50 kDa leucine-rich repeat (LRR) protein (7). It is 
mainly localized in the cytosol, but can also be found in the nucleus 
and mitochondria (8). RNH1 was the first LRR protein to be crys-
tallized, revealing a horseshoe-shaped 3D structure (9). The 
human RNH1 gene evolved via gene duplication and is conserved 
among mammalian species, with human, porcine, mouse, and rat 
RNH1 proteins sharing 66% identity (10).
Multiple biological roles have been proposed for RNH1. It 
binds to and inhibits ribonucleases, such as RNase A, RNase 1, 
eosinophil-derived neurotoxin (EDN, also known as RNase 2), and 
RNase 4 (7). RNH1 affinity for ribonucleases is the key determi-
nant factor for RNase cytotoxicity; only ribonucleases that evade 
RNH1 can kill a cell. RNH1 also binds to angiogenin (ANG), sug-
gesting a possible role in neovascularization (11), but the extent 
to which RNH1 may regulate angiogenesis remains unclear. 
Further, RNH1 contains numerous cysteine residues (e.g., 32 in 
human RNH1), whose sulfhydryl groups might play key structural 
roles and protect from oxidative damage (7, 12). There are several 
conflicting reports about the role of RNH1. For example, siRNA 
knockdown of RNH1 does not sensitize cells to noncytotoxic 
RNases, and its role in oxidative damage is not firmly established 
(7, 8, 12, 13). However, despite these observations, the physiologi-
cal functions of RNH1 remain unexplored.
In this study, we describe an unsuspected role for RNH1 in 
embryonic erythropoiesis and erythroid differentiation. We find 
that RNH1 is a ribosomal-associated protein that regulates eryth-
ropoiesis by controlling translation of the erythroid transcription 
factor (TF) GATA1. Like Gata1-deficient mice, Rnh1-deficient 
mice die from anemia in utero.
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(15). The presence of Pecam-1+ endothelial cells in Rnh1–/– embryos 
indicates that hemangioblasts were produced in these embryos 
and that the defect was hematopoietic specific.
The first wave of hematopoiesis is transient and takes place in 
the yolk sac, giving rise to a single lineage-restricted population of 
embryonic-primitive erythroid (EryP) cells (16). In both humans 
and mice, yolk sac–derived EryP cells support the rapid growth of 
the embryo during early embryonic development (17). Our obser-
vations so far are consistent with the view that embryonic death 
may be attributed to severely decreased blood cell formation and 
anemia. Interestingly, the phenotype of Rnh1-deficient embryo is 
similar to those of Gata1- and Gata2-deficient embryos (18). None-
theless, mRNA levels of Gata1 and Tal1/SCL, 2 TFs that are essential 
for embryonic erythropoiesis (19, 20), were not affected (Figure 2I) 
despite reduced erythroid cells in the Rnh1–/– yolk sac (Figure 2C). 
α-Fetoprotein (Afp), the fetal equivalent of serum albumin, was also 
similarly expressed in Rnh1+/+ and Rnh1–/– yolk sacs (Figure 2I). We 
also assessed the ability of E8–E9.5 yolk sac–derived cells to form 
erythroid colonies using a methylcellulose colony-forming assay. In 
comparison with Rnh1+/+ and Rnh1+/–, the number of Rnh1–/– colonies 
was significantly decreased (Figure 2J). Control yolk sac colonies 
displayed an erythroid burst-forming unit–like (BFU-E–like) mor-
phology and contained erythroid cells. Rnh1–/– yolk sac colonies had 
a similar morphology, but with pale color, and contained less mature 
erythroid cells (Supplemental Figure 2, A and B). FACS analysis of 
colony cells revealed that erythroid cells expressing Ter119 and CD71 
(also known as transferrin receptor 1) could develop from Rnh1- 
deficient progenitors, but with a markedly decreased frequency com-
pared with Rnh1-proficient cells (Supplemental Figure 2C). These 
data suggest that an intrinsic differentiation defect of progenitor cells 
precedes the appearance of anemia and the growth defect phenotype. 
Although the onset of erythropoiesis can occur in Rnh1–/– embryos, 
it is profoundly decreased.
Rnh1 expression during embryonic development. In the adult, 
Rnh1 is expressed ubiquitously. However, Rnh1 expression during 
embryonic development has not been investigated. Rnh1 expres-
sion increased from E8 to E9.5 (Figure 3A) and, at E9.5, was 7-fold 
higher in the yolk sac compared with the embryo proper (Figure 
3B), coinciding with the site of primitive erythropoiesis (17). It 
has been reported that RNH1 is highly expressed in erythrocytes 
(21). We indeed found colocalization of immunostainings for 
RNH1 and Ter119, a marker of erythroid cells, in the yolk sac and 
embryo proper of E10.5 WT embryos, in line with a role for RNH1 
in embryonic erythropoiesis (Figure 3C and Supplemental Figure 
3). High expression of the Rnh1 gene in Ter119+ erythroid cells 
during embryonic development concurs with a role for Rnh1 in 
embryonic erythropoiesis.
Rnh1 regulates erythroid differentiation. Hematopoietic stem/
progenitor cells (HSPCs) that give rise to primitive hematopoiesis 
are highly enriched in the population of c-Kit+CD41+ cells from 
the yolk sac (22–24). These cells are transient progenitor popu-
lations distinct from later HSC populations that emerge. FACS 
analysis revealed that the percentage of c-Kit+CD41+ (HSPC) cells 
present in yolk sacs was comparable in all genotypes (Figure 3D). 
This observation excludes the possibility that the phenotype of 
Rnh1-deficient embryos may result from defects in HSPC gener-
ation. The paucity of nucleated erythroid cells in blood islands of 
Results
Embryonic lethality in Rnh1-deficient mice. To gain insight into the 
biological function of RNH1, Rnh1-deficient (Rnh1–/–) mice were 
generated through homologous recombination (Figure 1, A and B). 
When Rnh1-heterozygous (Rnh1+/–) mice were intercrossed, both 
Rnh1+/+ (n = 77) and Rnh1+/– (n = 151) mice were observed at the 
expected 1:2 ratio, but Rnh1–/– mice were strikingly absent (Table 
1). Similar results were also found in Neo cassette–deleted Rnh1–/– 
mice (data not shown). We next examined embryonic develop-
ment and found that Rnh1–/– embryos developed normally before 
E7.25 (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI94956DS1), 
but showed overall growth retardation between E8.5 and E10, with 
a severe decrease in blood levels in the yolk sac and in the embryo 
proper (Figure 2, A and B, and Supplemental Figure 1B and Table 
1). At this time point, major developmental features, such as cho-
rioallantoic fusion, rotation of the embryo, neural tube closure, 
and formation of head structures, were present. The complete 
absence of viable embryos after E10.5 indicated an essential role 
for Rnh1 during this developmental window.
Defective embryonic erythropoiesis in Rnh1-deficient mice. His-
tological examination revealed a profound decrease of erythroid 
cells in yolk sac blood islands (Figure 2C) and in the placenta 
(Figure 2D). In addition, the few erythroid cells in yolk sac blood 
islands of Rnh1–/– embryos showed reduced staining with the heme- 
specific dye benzidine, indicative of a reduced load of hemoglobin 
(Figure 2E). Endothelium-lined blood vessels were, however, sim-
ilar in Rnh1+/– and Rnh1–/– yolk sacs (Figure 2C), and other tissues of 
mesodermal origin such as somites and myocardium were present 
(Supplemental Figure 1, C and D). We confirmed that Rnh1 mRNA 
was absent in the yolk sac of Rnh1–/– embryos (Figure 2F). Since 
compromised vasculogenesis could affect embryonic erythropoi-
esis (14), we checked blood-vessel formation in Rnh1–/– embryos 
by immunostaining with Pecam-1 (CD31) and by flow cytometry. 
Blood-vessel formation was intact in Rnh1–/– embryos, as judged 
by Pecam-1 (CD31) immunostaining (Figure 2H). Similar percent-
ages of CD31+ cells were also detected by flow cytometry in all 
genotypes, with a moderate increase in Rnh1–/– yolk sacs (Figure 
2G). Therefore, anemia was not associated with defective vasculo-
genesis. During development, the endothelial and hematopoietic 
lineages originate from a common precursor, the hemangioblast 
Table 1. Genotype table
Genotypes of litters obtained by intercrossing Rnh1+/–
Stages Number of pups +/+ +/– –/–
E8.5 32 8 13 11A
E9.5 78 22 35 21A
E10.5 28 5 15 0B
E11.5 16 5 11 0
Pups 228 77 151 0
AAbnormal compared with WT. BAll KO embryos were degenerated and 
residual tissue was found. Rnh1-heterozygous (Rnh1+/–) mice were 
intercrossed. Genotypes of offspring were determined at different 
gestational days or after birth, as shown.
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sis in Rnh1–/– embryos, we performed a transcriptome analysis 
on Rnh1+/+, Rnh1+/–, and Rnh1–/– yolk sacs. There was no change 
between Rnh1+/+ and Rnh1+/– gene expression patterns, but 628 
genes were significantly lower, including genes of mature erythro-
cytes and genes involved in erythrocyte differentiation, while 273 
genes were more expressed in Rnh1–/– compared with Rnh1+/+ (Fig-
ure 5A and Supplemental Table 1). A phenotype enrichment analy-
sis revealed hematopoietic defects, such as abnormal blood coag-
ulation, hemostasis, and erythrocyte physiology, as main gene 
signatures among downregulated genes, in tight agreement with 
hematopoiesis and erythroid differentiation defects observed in 
Rnh1–/– mice (Supplemental Figure 4A and Supplemental Table 2).
Several TFs are required for erythropoiesis. We applied 
gene set enrichment analysis (GSEA) in a large data set of ChIP- 
sequencing (ChIP-seq) studies to determine whether targets 
of hematopoietic TFs were differentially regulated in the tran-
scriptome of Rnh1–/– yolk sacs (see Methods). GSEA scores for 
most tested regulators, including essential erythropoietic regula-
tors such as GATA1, LDB1, TAL1 and PPARG, were remarkably 
similar, indicating that their target genes were less expressed in 
the Rnh1–/– yolk sac (Figure 5B and Supplemental Figure 4B and 
Supplemental Table 3). This global downregulation of hema-
topoietic TF target genes, but not the TFs themselves, suggests 
that a posttranscriptional mechanism affects TF gene function, 
particularly in the erythroid lineage. In support of this hypoth-
esis, a Western blot analysis performed on total Rnh1-deficient 
embryos revealed decreased protein levels of GATA1 (Figure 5C; 
see complete unedited blots in the supplemental material). We 
focused on GATA1 because it was top ranked by GSEA analysis 
and because it is an important hematopoietic TF, without which 
erythropoiesis does not take place at all developmental stages in 
mice and humans (26, 27). The GATA1 deficit in Rnh1–/– embryos 
did not entirely result from a reduced number of erythroid cells, 
Rnh1-deficient yolk sacs (Figure 2C) led us to analyze E8.5 and 
E9.5 yolk sac cells by flow cytometry for the erythroid markers 
Ter119 and CD71. This analysis revealed that EryP cells (Ter119+ 
and CD71+) were significantly decreased in Rnh1-deficient yolk 
sacs (Figure 3E), while HSPCs were not affected (Figure 3D). 
We also found more binucleated erythroblast in Rnh1–/– yolk sac 
(Figure 3F), indicating an ineffective erythropoiesis. Together, 
these data suggest that Rnh1 is required for efficient differentia-
tion of HSPCs into EryP cells, a process essential for embryonic 
growth and survival. Since colony assays are based on the capacity 
of these progenitors to give rise to erythroid cells in vitro, these 
observations explain why colony numbers are decreased (Figure 
2J), but not the actual frequency of HSPCs.
Decreased splenic erythropoiesis in Rnh1+/– adult mice. Heterozy-
gous (Rnh1+/–) mice survived normally and did not show any phe-
notypic abnormalities, suggesting that 1 allele of Rnh1 is sufficient 
for its function. Because our results suggest that Rnh1 regulates 
erythroid differentiation, we checked to determine whether Rnh1 
haploinsufficiency decreased adult erythropoiesis. While there 
was no difference in erythroid cell numbers in Rnh1+/– BM com-
pared with WT littermates (Figure 4, A and B), erythroid cells in 
the spleen were significantly decreased (Figure 4, C and D). All 4 
erythroid subpopulations, distinguished by differential expression 
of Ter119 and CD71 (25), were decreased in Rnh1+/– spleen com-
pared with Rnh1+/+ (Figure 4, C and D). Further, FACS forward 
scatter (indicator of cell size) was also increased in Rnh1+/– eryth-
roid cells, indicating decreased erythroblast maturation (25) (Fig-
ure 4E). In contrast, there was no difference in numbers of T cells, 
B cells, and macrophages in the spleen (Figure 4F). Therefore, 
Rnh1 is haplo-insufficient for erythropoiesis in the spleen, further 
pointing to the importance of Rnh1 in maintaining erythropoiesis.
RNH1 deficiency decreases Gata1 mRNA translation. To get 
clues on the mechanism(s) causing decreased erythropoie-
Figure 1. Generation of Rnh1–/– 
mice. (A) A 15.1 kb region used to 
construct the targeting vector was 
first subcloned from a positively 
identified C57BL/6 (RP23:210J2) 
BAC clone using a homologous 
recombination-based technique. 
The region was designed such that 
the long homology arm extended 
5.30 kb 3′ to exon 10. The short 
homology arm is located on the 5′ 
side of exon 2 and is 2.96 kb long. 
The Neo cassette replaces 6.89 
kb of the gene, including exons 
2–10. (B) DNA isolated from mouse 
embryos was genotyped by PCR. 
Primers were designed to distin-
guish WT and neo cassette gene 
sequence. 275 bp size corresponds 
to WT, and 200 bp size corresponds 
to knockout mice.
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translation, we profiled polysomes extracted from yolk sac cells. 
mRNAs contained in polysomes are bound to multiple ribosome 
units and actively translated; thus, the measure of polysome- 
associated mRNAs is an indication of their translation rate (3). 
as Gata1 mRNA levels were not reduced to the same degree as 
GATA1 protein levels, an observation based on the markedly 
decreased ratio of protein to mRNA (Figure 5, D and E). To deter-
mine whether decreased GATA1 protein levels reflected impaired 
Figure 2. Decreased embryonic 
erythropoiesis in Rnh1-deficient 
mice. (A and B) Morphology of E10 
Rnh1+/– and Rnh1–/– whole embryos 
(A) and embryos proper (B). Scale 
bars: 1 mm. (C) H&E-stained 
sections through visceral yolk sacs 
of Rnh1+/– and Rnh1–/–. Scale bars: 
20 μm. Thin arrows indicate blood 
cells; thick arrows indicate endothe-
lium layer. (D) Parasagittal section 
of placenta of Rnh1+/– and Rnh1–/–. 
Scale bars: 20 μm. Arrows indicate 
blood cells. (E) Benzidine-stained 
sections through visceral yolk sac of 
Rnh1+/– and Rnh1–/–. Arrow indicates 
blood cells. (F) qRT-PCR analysis of 
E9.5 yolk sac for Rnh1, normalized 
to 18S rRNA expression (n = 3–5). 
Data are shown as mean ± SEM. (G) 
CD31 mean fluorescence intensity 
analyzed by flow cytometry  
(n = 3) on E9.5 total yolk sac cells. 
(H) Pecam-1 (CD31) immunostaining 
of E9.5 Rnh1+/– and Rnh1–/– embryos. 
Scale bars: 500 μm. (I) qRT-PCR 
analysis on E9.5 yolk sac for the 
indicated mRNAs, normalized to 
18S rRNA expression (n = 3–5). Data 
are shown as mean ± SEM. (J) Total 
number of colonies observed when 
E8–E9.5 yolk sac cells were cultured 
for 7 days in methyl cellulose 
medium (n = 3–4). Data are shown 
as mean ± SEM. P values were 
determined by 2-tailed t test.
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rRNA ratios and RNA quality and found that both were compara-
ble in RNH1-KO and WT K562 cells (Supplemental Figure 9, A and 
B). Further, overexpression of an RNH1-mutant (RNH1ΔC) that 
does not bind to RNase1 also increased polysomes (Supplemental 
Figure 10, A–C; see complete unedited blots in the supplemental 
material). These results suggest that polysome stabilization by 
RNH1 might be independent of its RNAse inhibitor function. A 
recent study has suggested that GATA1-mutant human erythroid 
cells in culture failed to upregulate expression of translation appa-
ratus genes (29). In K562 cells, however, ribosome biogenesis and 
rRNA-processing genes were not reduced in the absence of RNH1 
(Supplemental Figure 11, A and B). Overall, these results suggest 
that RNH1 controls GATA1 translation.
RNH1 regulates erythroid differentiation in primary human 
CD34+ HSPCs. We evaluated whether RNH1 also regulates differ-
entiation of primary adult human CD34+ HSPCs to the erythroid 
lineage. In these cells, RNH1 was knocked down using shRNAs 
and erythroid and myeloid differentiation was induced separate-
ly, as shown schematically in Figure 9A. RNH1 knockdown effi-
ciently decreased RNH1 protein levels in CD34+ HSPCs (Figure 
9B; see complete unedited blots in the supplemental material). 
Surface expression of CD71 (loss of CD71 indicates erythroid mat-
uration) remained high in RNH1-knockdown cells (Figure 9C and 
Supplemental Figure 12), suggesting decreased erythroid matura-
tion. RNH1-knockdown cells also showed decreased enucleation, 
as determined by Hoechst 33342 staining (Figure 9D). Further, 
morphological analysis of cytospins showed decreased maturation 
and enucleation in RNH1-knockdown cells (Figure 9F). However, 
there was no difference in myelopoiesis, as determined by CD16/
CD11b FACS staining, and in mature neutrophil numbers (Figure 9, 
E and F). In differentiated myeloid cells, RNH1 knockdown did not 
affect mRNA and protein levels of the myeloid TFs PU.1 (SPI1) and 
C/EBPα (CEBPA) (Figure 9, G and H; see complete unedited blots 
in the supplemental material). In contrast, GATA1 protein, but not 
mRNA levels, were decreased in erythroid cells knocked down for 
RNH1 (Figure 9, I and J; see complete unedited blots in the supple-
mental material). These results support our previous findings in 
mice and in human K562 cells that RNH1 controls GATA1 transla-
tion and erythroid differentiation.
Interestingly, we also observed decreased protein levels 
of other erythroid TFs, FOG1 (ZFPM1) and KLF1, in RNH1- 
knockdown cells (Figure 9, J and K; see complete unedited blots 
in the supplemental material). mRNA levels of KLF1 were 
de creased in RNH1-knockdown cells (Figure 9I). Since GATA1 
directly controls KLF1 expression (30, 31), the reduction in GATA1 
levels may explain decreased mRNA and protein levels of KLF1. In 
the case of FOG1, similarly to what occurred with GATA1, mRNA 
levels were not decreased in RNH1-knockdown cells, suggesting 
that RNH1 might also control FOG1 translation. Overall, these 
results suggest that RNH1 regulates erythropoiesis and can con-
trol GATA1 translation in human CD34+ progenitors. RNH1 may 
also control translation of other genes that affect erythropoiesis.
RNH1 is present in ribosome fractions and binds to the small ribo-
somal subunit. We next wondered how RNH1 was molecularly con-
nected to the translation machinery. In K562 lysates, although the 
majority of RNH1 was found in a postribosomal fraction (S100), 
RNH1 was also detected in a polysome-enriched fraction (P100) 
Polysomes were decreased in Rnh1–/– cells and, when normalized 
to 18S rRNA, polysome and monosome fractions contained lower 
levels of Gata1 mRNA than those of Rnh+/–, while mRNA levels 
of another erythroid TF, Hoxb4, remained comparable in Rnh1–/– 
and Rnh1+/– polysomes (Figure 5, F and G). These results suggest 
that, even though the overall translation rate is affected in Rnh1–/– 
cells, Gata1 mRNA translation is further specifically decreased. 
Global protein levels were comparable in E10 embryos, as seen 
with Ponceau S staining (Figure 5C), and also CD31 levels were 
not decreased in Rnh1–/– endothelial cells (Figure 2H). A specific 
decrease of Gata1 mRNA translation was also observed in cells 
deficient for RP RPS19, which is mutated in DBA patients (6). In 
support of an upstream role of RNH1 in GATA1 expression, tran-
sient expression of GATA1 in yolk sac Rnh1–/– cells restored the 
usual frequency of erythroid colonies in a methylcellulose colony- 
forming assay (Figure 6, A and B, and Supplemental Figure 5). 
Taken together, these results suggest that RNH1 is required for 
efficient recruitment of Gata1 mRNA to the ribosome complex.
RNH1 regulates erythroid differentiation by controlling GATA1 
translation in human erythroleukemia K562 cells. We wanted to 
confirm some of the results obtained in Rnh1-deficient mice 
using a human cell line. For this purpose, we knocked out RNH1 
using the CRISPR/cas9 system in the erythroleukemia cell line 
K562, which expresses embryonic globin genes (28) (Figure 7A; 
see complete unedited blots in the supplemental material), and 
indeed reproduced many of the findings obtained in Rnh1–/– mice: 
RNH1-KO cells expressed less GATA1 protein compared with WT 
cells, even though GATA1 mRNA levels were similar (Figure 7, A 
and B). The percentage of benzidine-positive cells was decreased 
in unstimulated RNH1-KO cells (Figure 7C) and in hemin-treated 
cells (Figure 7D), suggesting a defect in erythroid differentiation. 
We also found fewer polysomes in RNH1-KO cells (Figure 7E) 
and decreased GATA1 mRNA abundance in monosome and poly-
some fractions compared with other investigated erythroid genes 
(Figure 7F). When cells were labeled for 4 hours with the methi-
onine analogue l-azidohomoalanine (6), less label was incorpo-
rated into GATA1 immunoprecipitates from RNH1-KO K562 cells 
than from control cells, further suggesting that GATA1 transla-
tion is impaired in the absence of RNH1 (Supplemental Figure 6, 
A–C; see complete unedited blots in the supplemental material). 
Furthermore, an RNA-sequencing (RNA-seq) analysis showed 
significant downregulation of GATA1 target genes in RNH1-KO 
cells compared with WT (Supplemental Figure 7 and Supplemen-
tal Table 4). Finally, transient expression of GATA1 in RNH1-KO 
cells restored the usual frequency of benzidine-positive cells, in 
line with a role of RNH1 upstream of GATA1 expression (Supple-
mental Figure 8; see complete unedited blots in the supplemental 
material). Moreover, overexpression of Flag-RNH1 in WT K562 
cells increased the relative abundance of polysomes, increased 
globin mRNA levels, and increased the percentage of benzidine- 
positive cells (Figure 8, A–E; see complete unedited blots in 
the supplemental material), further indicating that RNH1 is 
functional in human K562 cells in a cell-intrinsic manner.
RNH1 is known to inhibit ribonucleases and protect RNA, 
raising the question of whether this function might contribute to 
decreasing or increasing polysomes in RNH1-deficient or overex-
pressing cells, respectively. To address this, we checked 28S/18S 
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(Figure 10A; see complete unedited blots in the supplemental mate-
rial) and in the polysome fractions of a sucrose gradient (Figure 10B; 
see complete unedited blots in the supplemental material). After 
high-salt (0.5 M KCl) treatment, some RNH1 remained associated 
with the 80S monosome fraction (Figure 10C; see complete unedited 
blots in the supplemental material), while after puromycin-induced 
dissociation of ribosomes into 40S and 60S subunits (32), RNH1 
was found associated to the 40S subunit (Figure 10D; see complete 
unedited blots in the supplemental material). The salt conditions 
used in this experiment are known to remove translation factors that 
Figure 3. Rnh1 is expressed in embryonic erythropoiesis and 
regulates erythroid differentiation. (A and B) qRT-PCR analysis for 
Rnh1 on whole embryos from different embryonic days as shown 
(A) and E9.5 yolk sacs and embryos proper (B). mRNA levels are 
normalized to 18S rRNA expression (n = 3–4). Data are shown as 
mean ± SEM. (C) Immunostaining of a WT E10.5 yolk sac with RNH1 
and the erythroid marker TER119. Original magnification ×20. (D) 
Flow cytometry analysis for HSPCs on E9.5 yolk sac cells (n = 3–4). 
(E) Flow cytometry analysis for CD31-negative erythroid cells on E8.5 
and E9.5 yolk sac cells (n = 3–4). Data are shown as mean ± SEM. (F) 
Cytospins from yolk sac cells were stained with Pappenheim stain 
(left). Binucleated erythroblasts are indicated by asterisks. Repre-
sentative bar graph showing percentage of binucleated cells (right) 
(n = 3). Original magnification ×400. Data are shown as mean ± SEM. 
P values were determined by 2-tailed t test.
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associate with ribosomes, aminoacyl-tRNA synthetases, and some 
protein kinases, but not intrinsic RPs (32). These results suggest 
that RNH1 can directly interact with the small ribosomal subunit. 
In order to confirm the interaction of RNH1 with ribosomes, Flag-
RNH1 was immunoprecipitated from transfected or untransfected 
K562 cells and interacting proteins were identified by mass spec-
trometry (MS) (Supplemental Table 5). RPs and proteins involved in 
RNA processing were among the top enriched functional categories 
that bound to RNH1 (Figure 11A). This was confirmed by Western 
blot for RPs RPL11 and RPS3, while 2 proteins not found in the MS 
analysis, the ribosome protein RPS6 and the elongation factor EEF2, 
were negative by Western blot in the Flag-RNH1 immunoprecipitate 
(Figure 11B; see complete unedited blots in the supplemental mate-
rial). Further supporting these data, RNH1 was present in a recently 
analyzed mammalian riboproteome (33). Collectively, these results 
indicate that RNH1 interacts with RPs and support the role of RNH1 
in translation and erythropoiesis.
Discussion
RNH1 is known to inhibit ribonucleases and protect RNA from 
degradation. However, the precise biological role of RNH1 in vivo 
remains unexplored. Our results have uncovered a crucial function 
for RNH1 in the regulation of erythropoiesis by controlling GATA1 
translation. Embryonic erythropoiesis starts between E7 and E7.5 
by producing primitive erythroid cells from a transient wave of 
committed progenitors in the yolk sac (16). These primitive eryth-
roid cells support the rapid growth of the embryo during early 
embryonic development. We demonstrate that Rnh1 expression 
localizes to erythroid cells at the onset of primitive erythropoiesis 
and that Rnh1 deficiency resulted in a lethal decrease in erythroid 
differentiation and the hemoglobin content per cell. The anemia 
phenotype observed in Rnh1–/– embryos was not associated with 
defective vasculogenesis and HSPC generation, since blood vessel 
formation and HSPC generation were intact. Further, Rnh1 haplo-
insufficiency decreased adult erythropoiesis in the spleen, further 
pointing to the importance of Rnh1 in maintaining erythropoiesis.
Similarly, RNH1 deficiency in human K562 cells and RNH1 
knockdown in primary CD34+ HSPCs reduced erythroid differen-
tiation, suggesting that its role is conserved across species and that 
it can play a cell-intrinsic function. Interestingly, the transcrip-
tome of Rnh1–/– yolk sac cells revealed that the expression levels of 
erythroid TFs were not deficient, but that their target genes were 
Figure 4. Decreased splenic erythropoie-
sis in Rnh1+/– adult mice. (A and B) Flow 
cytometry analysis for erythroid cells of 
8-week-old Rnh1+/– and Rnh1+/+ mouse 
BM (n = 6 mice). (C and D) Flow cytometry 
analysis for erythroid cells of 8-week-old 
Rnh1+/– and Rnh1+/+ mouse spleens (n = 6 
mice). Different erythroblast subpopula-
tions were selected and are indicated as I to 
IV. I, proerythroblasts, II, basophilic eryth-
roblasts; III, late basophilic and chromato-
philic erythroblasts; IV, orthochromatophilic 
erythroblasts. Data are shown as mean 
± SD. (E) Flow cytometry forward-scatter 
distribution histograms of Rnh1+/– and 
Rnh1+/+ mouse spleen erythroid cells gated 
on total Ter119+ cells (left) and on region 
II (right). Data are shown as mean ± SD. 
(F) Flow cytometry analysis for lymphoid 
and myeloid populations on 8-week-old 
Rnh1+/– and Rnh1+/+ mouse spleen B cells, T 
cells, and macrophages (n = 6 mice). FSC-A, 
forward scatter area. Data are shown as 
mean ± SEM. P values were determined by 
2-tailed t test.
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Methods
Generation of Rnh1–/– mice. Rnh1 targeting vector (Figure 1A) was elec-
troporated into hybrid (C57BL/6 × 129/SvEv) embryonic stem (ES) 
cells. Homologous recombinant ES cells were identified by Southern 
blot analysis and microinjected into blastocysts. Offspring were back-
crossed to C57BL/6 mice, and germline transmission was confirmed 
by PCR of tail genomic DNA. Screening of Rnh1-deficient mice by PCR 
genotyping was carried out using the following primers on embryo or 
ear genomic DNA: 5′-CTGATAACTTATTTCCGGGATAC (forward 
in intron 1), 5′-ACCACTTCGTATTGCTGGA (reverse in exon 2), and 
5′-TAAGCTTGGATCCGTTCTTC (reverse in PGK-NEO cassette). 
We used 8-week-old male Rnh1+/+ and Rnh+/– mice (n = 6 mice) to ana-
lyze different cell populations in spleen and BM.
RNA preparation and qRT-PCR. Total RNA was isolated from 
embryos, yolk sacs, and K562 cells using the QIAGEN RNeasy Kit 
according to the manufacturer’s protocol. Reverse transcription and 
real-time PCR (RT-PCR) from total RNA was carried out as described 
previously (36). The SYBR Green Dye detection system was used for 
quantitative real-time PCR on Light Cycler 480 (Roche). Gene-specific 
primers (Microsynth) used are listed in Supplemental Table 6. Controls 
consisting of ddH2O were negative for target and housekeeping genes.
Gene expression analysis. Total RNA from E9.5 yolk sacs of different 
genotypes (Rnh1+/+, Rnh1+/–, and Rnh1–/–) was isolated and purified with 
the QIAGEN RNeasy Kit according to the manufacturer’s protocol. All 
RNA amounts were monitored with a NanoDrop ND-1000 spectropho-
tometer, and the RNA quality was assessed using RNA 6000 NanoChips 
with the Agilent 2100 Bioanalyzer. For each sample, 100 ng of total RNA 
was amplified using the WT Sense Strand Target Labelling Kit (Affymet-
rix, catalog 900223); 5.5 μg of the resulting sense cDNA was fragmented 
by uracil DNA glycosylase (UDG) and apurinic/apyrimidic endonuclease 
1 (APE 1) and biotin-labeled with terminal deoxynucleotidyl transfer-
ase (TdT) using the GeneChip WT Terminal Labelling Kit (Affymetrix, 
900671). Affymetrix Mouse Gene 1.0 ST arrays were hybridized with 
2.7 μg of biotinylated target at 45°C for 17 hours and washed and stained 
according to the protocol described the in the Affymetrix GeneChip 
Expression Analysis Manual (Fluidics protocol FS450_0007). The arrays 
were scanned using GeneChip Scanner 3000 7G (Affymetrix), and raw 
reduced. This is in line with our observation that RNH1 associates 
with RPs to favor polysome formation and enhance translation. 
Supporting this, GATA1 mRNA levels were not affected, but pro-
tein levels were decreased. Further, transient expression of GATA1 
in RNH1-deficient mouse yolk sac cells and K562 cells restored 
the erythroid differentiation defect observed in RNH1-deficient 
cells, suggesting a role of RNH1 upstream of GATA1 expression.
Mutations in RPs interfere with ribosome biogenesis, which 
is considered as the main pathological mechanism for DBA 
(4). DBA is a rare congenital pure red cell aplasia characterized 
by anemia, macrocytosis, and reticulocytopenia (4). In DBA 
patients, mutation of RPs, such as RPS19, leads to impaired ribo-
somal biogenesis and causes a defect in translation of GATA1 and 
erythroid-related genes (5, 6). Similarly, RNH1 is a ribosome- 
associated protein expressed by erythroid cells whose deficiency 
caused decreased GATA1 translation and defective differentia-
tion of erythroid cells (Figure 12). Defects in ribosomal biogen-
esis can lead to TP53 upregulation and apoptosis (34). None-
theless, impaired erythropoiesis in Rnh1-deficient embryos was 
not associated with p53-dependent apoptosis, since we did not 
find TP53 upregulation or enrichment of TP53-related apoptotic 
genes (Supplemental Table 1). Although this work focused mainly 
on GATA1, we consider it likely that RNH1 regulates translation 
of other erythroid-specific genes. Determining precisely how 
this specific regulation of translation takes place requires fur-
ther investigation. RNH1 is only present in vertebrates and was 
proposed to be an intracellular sentry, since it protects cytosolic 
RNA from extracellular ribonucleases (35). However, our com-
bined functional and systems-level analyses show that this is not 
the sole or perhaps even the main function of RNH1 in vivo. In 
conclusion, we present a function for RNH1 in GATA1 translation 
and erythropoiesis. These data add RNH1 to the list of ribosomal- 
associated factors that regulate specific mRNA translation (1). 
This warrants further studies on RNH1 and may provide novel 
therapeutic opportunities for erythropoiesis-related disorders.
Figure 5. RNH1 deficiency decreases GATA1 protein levels. (A) Up- and 
downregulated genes of E9.5 yolk sacs from Rnh1–/– mice compared with 
WT (probability of false positive < 0.1). Adj, adjusted. (B) Target enrich-
ment analysis of essential erythroid TF targets in E9.5 yolk sacs from 
Rnh1–/– mice. Bars correspond to the GSEA normalized enrichment scores 
of target sets extracted from a collection of ChIP-seq studies (n = 52). 
NS corresponds to an adjusted P value of greater than 0.01. Asterisks 
indicate key regulators of erythropoiesis. (C) Western blot analysis of total 
protein lysates isolated from E10 embryos, using indicated antibodies. 
Nitrocellulose membranes were stained with Ponceau S to demonstrate 
protein loading. Blots are representative of 3 independent experiments. 
(D) qRT-PCR analysis of E10 embryos for indicated mRNAs, normalized 
to 18S rRNA (n = 3). Data are shown as mean ± SEM. (E) Protein/mRNA 
ratios were determined using densitometric values of proteins, and 18S 
rRNA–normalized mRNA expression values for E10 total embryos. Data 
are expressed as mean ± SD. (F) Sucrose gradient polysome profiles for 
Rnh1+/– and Rnh1–/– yolk sac–derived cells from E10 embryos. Arrow shows 
the direction of the sucrose gradient from low to high density. Data are 
representative of 3 independent experiments. (G) qRT-PCR analysis for 
indicated mRNAs in monosome (M), light polysome (LP), and heavy 
polysome (HP) fractions derived from E10 Rnh1+/– and Rnh1–/– yolk sac cells. 
mRNA levels were normalized to 18S rRNA expression. Data are shown as 
mean ± SEM. Data are representative of 3 independent experiments.  
P values were determined by 2-tailed t test.
Figure 6. GATA1 overexpression rescues erythroid phenotype in Rnh1- 
deficient yolk sac cells. (A) Total number of colonies observed in control 
and GATA1- infected Rnh1-deficient yolk sac cells that were cultured for 7 
days in methyl cellulose medium (n = 3). Data are shown as mean ± SD. P 
values were determined by 2-tailed t test. (B) Cytospin images of erythroid 
cells derived from methyl cellulose colonies of control and GATA1-infected 
cells. More mature erythroid cells were observed in GATA1-infected cells. 
Original magnification ×400.
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R environment (http://www.bioconductor.org). Normalized expression 
signals were calculated from Affymetrix CEL files using the RMA normal-
ization implemented in the Affy package (37), and differential expression 
analysis was performed using the Rank Products package (38).
data were extracted from the scanned images and analyzed with the Affy-
metrix Power Tools software package. Affymetrix Hybridization quality 
was assessed using Expression Console software (Affymetrix). Microar-
ray analysis was performed using various Bioconductor packages in the 
Figure 7. RNH1 deficiency 
decreases erythroid differ-
entiation and GATA1 protein 
levels in K562 cell. (A) Total 
protein lysates of WT and 
RNH1-KO K562 cells were 
analyzed by Western blot 
with the indicated antibodies. 
K562 cells were positive for 
BCR-ABL oncogene. Blots are 
representative of 3 indepen-
dent experiments. (B) qRT-
PCR analysis for GATA1 mRNA 
levels in K562 cells, normal-
ized to 18S rRNA expression. 
Data are shown as mean ± SD 
and are representative of 3 
independent experiments. (C) 
Number of benzidine-positive 
K562 cells. Data are shown as 
mean ± SD and are represen-
tative of 3 independent exper-
iments. (D) K562 cells were 
treated with hemin (25 μM) 
for 3 days and analyzed for the 
presence of benzidine-positive 
cells. Data are shown as mean 
± SD and are representative of 
3 independent experiments. 
Original magnification ×200. 
(E) Polysome profiles for WT 
and RNH1-KO K562 cells. 
Data are representative of 3 
independent experiments. (F) 
qRT-PCR analysis for indicated 
mRNAs in monosome and 
polysome fractions derived 
from WT and RNH1-KO K562 
cells, normalized to 18S rRNA 
expression. Data are shown as 
mean ± SD and are repre-
sentative of 3 independent 
experiments. P values were 
determined by 2-tailed t test.
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sterile conditions from Rnh1+/+, Rnh1+/–, and Rnh1–/– embryos. Cells 
were isolated from yolk sacs by treatment with 0.1% collagenase in 
PBS and 20% fetal calf serum for 30 minutes at 37°C before mechan-
ical disaggregation, as described previously (20). Total yolk sac cells 
were cultured for 7 days in methylcellulose semisolid medium con-
taining all essential growth factors that support growth of erythroid 
progenitors (M3436, Stem Cell Technologies).
Flow cytometry and cell sorting. Single-cell suspensions were pre-
pared from mouse yolk sac and adult BM or spleen. Cells were stained 
with monoclonal antibodies specific for CD41 (clone MWReg30), 
CD117 (clone 2B8), CD31 (clone 390), Ter119 (clone TER-119), CD71 
(clone R17217), F4/80 (clone BM8), CD11b (clone M1/70), CD19 
(clone eBio1D3), and CD3 (clone 17A2). All antibodies were pur-
chased as FITC, phycoerythrin (PE), PE-Cy5, PE-Cy7, APC–eFluor 
780, Alexa Fluor 700, or PerCP–eFluor 710 conjugates from eBiosci-
ences. Cells were either acquired on a BD LSRII Flow Cytometer or 
sorted on a FACSAria I Cell Sorter (BD Biosciences). Data were ana-
lyzed with FlowJo (version 9.3.1, TreeStar Inc.) software. For human 
Phenotype enrichment analysis. We applied the Phenotype Ontology 
Enrichment program available in the MouseMine database (http://
www.mousemine.org/mousemine/begin.do) to determine phenotypes 
significantly enriched among downregulated genes in Rnh1–/– mice. 
Enriched phenotypes are related to spontaneous, chemically induced, 
or targeted mutations of mouse genes. The complete list of significant 
phenotypes (Benjamini-Hochberg adjusted P values < 0.05) is found in 
Supplemental Table 2.
Target enrichment analysis. The collection of 52 ChIP-seq stud-
ies was obtained from the HemoChIP compendium (39). For each 
ChIP-seq study, we extracted a list of targets by selecting genes con-
taining at least 1 binding site for the TF in the 2 kb region around 
the transcription start site. The GSEA test statistic (40) was used to 
determine upregulation or downregulation of TF targets in Rnh1–/– 
mice. Complete GSEA results and target gene sets are available in 
Supplemental Table 3.
Hematopoietic colony formation assays. E8, E8.5, and E9.5 yolk sacs 
were dissected without contamination from maternal tissue under 
Figure 8. RNH1 induces globin gene expression in K562 ells. (A) RNH1 expression in stable K562 cells expressing mock or Flag-RNH1 vector by West-
ern blot. Blots are representative of 2 to 3 independent experiments. (B) RNH1 expression in stable K562 cells expressing mock or Flag-RNH1 vector by 
qRT-PCR. Relative mRNA expression was normalized to HPRT expression. Data are shown as mean ± SEM. Data are representative of 3 independent 
experiments. (C) Sucrose gradient polysome profiles for mock- or RNH1-expressing stable K562 cells. Arrows show direction of the sucrose gradient from 
less to more dense. Data are representative of 3 independent experiments. (D) qRT-PCR analysis for globin genes in stable K562 cells expressing mock or 
Flag-RNH1 vector. Data expressed mRNA levels normalized to HPRT expression. Data are shown as mean ± SEM. (E) Percentage of benzidine-positive cells 
in mock or Flag-RNH1 vector–expressing stable K562 cells. Data are shown as mean ± SEM. Data are representative of 3 independent experiments.  
P values were determined by 2-tailed t test.
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ogy Inc.), human RNH1 (catalog sc-365783, Santa Cruz Biotechnolo-
gy Inc.), human FOG (catalog sc-376189. Santa Cruz Biotechnology 
Inc.), human GATA1 (catalog 4591, Cell Signaling Technology), BCR 
(catalog 3902, Cell Signaling Technology) and RPS6 (catalog 2317, Cell 
Signaling Technology), human C/EBPα, (catalog 2295, Cell Signaling 
Technology), anti-human PU.1 (catalog 2258, Cell Signaling Technol-
ogy), EEF2 (catalog 2332, Cell Signaling Technology), β-actin (catalog 
ab8227, Abcam), and human EKLF/KLF1 (catalog ab2483, Abcam).
Histology. Embryos were embedded in paraffin, and sections were 
used for H&E staining with routine protocols. Similar sections were used 
for benzidine staining. Cytospins were prepared from yolk sac cells and 
stained with Pappenheim stain (May-Grünwald and Giemsa, Fluka).
CRISPR/CAS9-mediated knockout cell line generation. CRIS-
PR sequences targeting exon 2 (RNH1-KO-1) and exon 3 (RNH1-
KO-2) of human RNH1 were designed using the online-available 
CRISPR design tool developed by the F. Zhang laboratory (http://
crispr.mit.edu/). The seed sequences preceding the protospacer 
adjacent motif (PAM) were the following: RNH1-1 oligo 1, 5′-CAC-
CGCGGCGTGCATTGCGTGCTCC-3′; RNH1-1oligo 2, 5′-AAAC-
GGAGCACGCAATGCACGCCGC-3′; RNH1-2 oligo 1, 5′-CAC-
CGGGGTGCGTAGTGTGCTGGAC-3′; and RNH1-2 oligo 2, 
5′-AAACGTCCAGCACACTACGCACCCC-3′. Nucleotides in italics 
show the overhangs necessary for incorporation into the restriction 
enzymatic site BbsI of LentiCRISPR-v2 vector expressing Cas9 and 
sgRNA (Adgene, catalog 52961) (41). Lentiviruses were produced in 
293T cells as previously described (42). K562 cells were infected with 
lentiCRISPv2 viruses targeting RNH1-1, RNH1-2, or control. Positive 
cells were selected with 2 μg/ml puromycin. RNH1 expression was 
assessed by Western blot. To obtain full KO cell lines, populations 
were cloned by limiting dilution and tested again by Western blot. All 
the generated K562 clones tested negative for mycoplasma contami-
nation using the MycoAlert Mycoplasma Detection Kit (Lonza, catalog 
LT07-318). K562 cells were from ATCC, and the presence of the BCR/
ABL fusion gene was authenticated by Western blot (Figure 7A) and 
cytogenetics (data not shown).
RNA-seq and analysis. Total RNA from control K562 and RNH1-KO 
cells was isolated and purified with QIAGEN RNeasy Kit according to 
the manufacturer’s protocol. We prepared Illumina TruSeq stranded 
mRNA libraries. The libraries were subjected to a preparative size 
selection on a PippinHT instrument to exclude library molecules with 
insert sizes of less than 300 bp. Libraries were then sequenced with 2 
× 150 bp reads on an Illumina HiSeq3000 instrument.
RNA-seq reads were mapped to the human reference genome 
(GRCh38, build 81) using Tophat v. 2.0.11 (43). We then used HTseq-
count v. 0.6.1 (44) to count the number of reads per gene and DESeq2 
v.1.4.5 (45) to test for differential expression between groups of sam-
ples. The outcome of the DESeq2 analysis was taken to perform GSEA 
using the SetRank method (46). This algorithm principally discards 
gene sets that have initially been flagged as significant, if their signifi-
cance is merely due to the overlap with another gene set. This method 
then calculates the P value of a gene set utilizing the ranking of its 
genes in the ordered list of P values as determined by DESeq2. We 
constructed a gene set database that consisted of the target gene sets 
of the GATA1 TF. Next, this database was complemented with all path-
ways that significantly intersect (Fisher’s exact test, Holm-corrected P 
≤ 0.01) with GATA1 target gene sets. The pathway collections searched 
came from the following databases: BIOCYC (47), Gene Ontology 
CD34+ differentiation experiments, cells were stained with anti- 
human monoclonal antibodies specific for CD11b (clone ICRF44), 
CD13 (clone WM-15), CD16 (clone eBioCB16), CD71 (clone OKT9), 
and CD235a (clone HIR2, also GA-R2). All antibodies were purchased 
as FITC, PE, or APC from eBiosciences. CD34 (clone AC136) anti-
body was from Miltenyi Biotec. Hoechst 33342 fluorescent nuclear 
stain (ImmunoChemistry Technologies) was added at a dilution of 
1:200 at least 15 minutes before analysis. Data were acquired on a 
CytoFLEX S Flow Cytometer (Beckman Coulter). Data analysis was 
carried out with FlowJo 10.2 (FlowJo LLC).
Immunostaining. Embryos and yolk sacs were fixed with 4% PFA 
in PBS for 2 hours and then washed with PBST (PBS + 0.3% Triton 
X-100). After washing, embryos were blocked for 4h with blocking 
buffer (contains 5% donkey serum and 0.5% BSA in PBS), and then 
incubated with primary antibody either Pecam-1 (clone MEC 13.3) 
(BD Bioscience) or RNH1 (catalog H00006050-D01P, Abnova) and 
Ter119 (catalog 14-5921-82, eBioscience) in blocking buffer over-
night at 4°C. After washing with PBST, embryos were incubated over-
night with Alexa Fluor secondary antibodies (Invitrogen) in blocking 
buffer and rinsed with PBST. Microscopy analyses were carried out 
using a Leica Stereomicroscope or a Time Lapse Inverted Microscope 
(Axio Observer.Z1).
Immunoblotting. Total mouse embryo-derived cells, human K562 
cells, CD34+ progenitor cells, erythroid cells, and myeloid cells were 
resuspended in lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1% [vol/
vol] Nonidet-P40, 10 mM EDTA). Extracts were used for immunoblot. 
Nitrocellulose membranes were stained with Ponceau S for similar 
protein loading control. The following antibodies were used: RNH1 
(catalog H00006050-D01P, Abnova), mouse GATA1 (catalog Sc-265, 
Santa Cruz Biotechnology Inc.), RPS3 (catalog sc-135390, Santa Cruz 
Biotechnology Inc.), RPL11 (catalog sc-25931, Santa Cruz Biotechnol-
Figure 9. RNH1 knockdown decreases GATA1 protein levels and erythroid 
differentiation in primary human CD34+ HSPCs. (A) Schematic illustration 
showing differentiation of human CD34+ HSPCs into mature erythrocytes 
and neutrophils. (B) Western blot analysis of RNH1 in CD34+ HSPCs after 
4 days of transduction. (C) Representative histogram plot showing CD71 
surface expression on day 12 of erythroid differentiation (n = 3). shScram, 
ShRNA Scrambled. (D) Flow cytometry analysis for CD235a+ and Hoechst 
33342– erythrocytes on day 12 of differentiation (n = 3). Data are shown as 
mean ± SD. (E) Flow cytometry analysis for CD11b+ and CD16+ neutrophils on 
day 12 of differentiation (n = 3). Data are shown as mean ± SD. (F) Cytospin 
images of erythroid (right) and myeloid (left) differentiated cells at the 
indicated days of differentiation, stained with May-Grünwald-Giemsa. 
Representative bar graph on the left shows percentage of morphologically 
mature erythrocytes (upper panel) and mature neutrophils (lower panel) 
at day 12 of differentiation (n = 3). Data are shown as mean ± SD. Original 
magnification ×400. (G) qRT-PCR analysis for indicated mRNAs in scram-
bled and RNH1-knockdown myeloid cells at day 6 of differentiation (n = 3), 
normalized to 18S rRNA expression. Data are shown as mean ± SD. (H) Total 
protein lysates of scrambled and RNH1 knockdown myeloid cells at day 6 of 
differentiation were analyzed by Western blot with the indicated antibod-
ies. (I) qRT-PCR analysis for indicated mRNA expression in scrambled and 
RNH1-knockdown erythroid cells at day 6 of differentiation (n = 3) normal-
ized to 18S rRNA expression. Data are shown as mean ± SD. (J and K) Total 
protein lysates of scrambled and RNH1-knockdown erythroid cells at day 6 
of differentiation were analyzed by Western blot with the indicated anti-
bodies. Right side in figure J, densitometric analysis for proteins by ImageJ 
(NIH). Values were normalized to β-actin. Data are expressed as mean ± SD 
(right). All blots are representative of 3 independent experiments. P values 
were determined by 2-tailed t test.
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monosome and polysome gradient fractions. Gene-specific primers 
(Microsynth) were used as listed in Supplemental Table 6.
Fractionation of ribosome. Polysome-enriched pellet (P100) and a 
postpolysomal supernatant (S100) were prepared from cytoplasmic 
extracts as reported previously (32). To completely dissociate 40S and 
60S ribosomal subunits, polysome-enriched pellets were resuspended 
in a buffer containing 3 mM MgCl2 and 500 mM KCl, and puromy-
cin was added to a final concentration of 1 mM as reported previously 
(32). Samples were incubated at 37°C for 15 minutes and centrifuged 
twice for 15 minutes at 30,000 g, and the supernatant was loaded on 
a linear sucrose gradient (10%–30%) in the same buffer. The gradient 
fractions were collected as described above. Following fractionation, 
proteins were isolated by precipitating with methanol and chloroform 
method and Western blotted as described above with anti-RPL11, anti-
RPS3 (Santa Cruz Biotechnology Inc.), anti-RPS6 (Cell Signaling), and 
anti-RNH1 (Abnova).
Generation of RNH1 expression plasmids. The sequence encoding 
human full-length RNH1 was amplified by PCR and subcloned into the 
mammalian expression vector pCR3 in frame with the N-terminal Flag 
or VSV tag. Using the Site-Directed Mutagenesis Kit (Agilent technolo-
gies), we generated different RNH1 mutant plasmids and checked their 
binding with RNase1 (54) (see also Supplemental Figure 10A). RNase1 
expression plasmid with the C-terminal MYC/Flag tag was purchased 
from Origene.
Generation of stable K562 cells expressing Flag-RNH1 and RNH1ΔC. 
Flag-RNH1or RNH1ΔC was further subcloned into retroviral vector 
pMSCVpuro (Clonetech). Retroviral vector pMSCVpuro-Flag-RNH1 
or RNH1ΔC was cotransfected with the helper plasmids VSV-G and 
Hit60 into HEK293T cells using PEI transfection reagent. Culture 
supernatants containing recombinant viral particles were harvested 
(48), KEGG (49), Pathway Interaction Database (50), REACTOME 
(51), and WikiPathways (52). The purpose of adding these additional 
gene sets was to make sure that the observed significance of the 
GATA1 target gene set was not purely due to this set intersecting with 
a more significant pathway.
Ribosome profile analysis by sucrose gradient density ultracentrifuga-
tion. Yolk sac cells derived from Rnh1+/– and Rnh1–/– were pooled and 
cultured for 7 days in methylcellulose semi-solid medium containing 
all essential growth factors that support erythroid progenitors (M3436, 
Stem Cell Technologies) to get enough cells. Approximately 2 × 106 yolk 
sac–derived cells and 5 × 106 K562 cells were washed with PBS contain-
ing cycloheximide (CHX) (100 ug/ml) and resuspended in 200 μl of 
hypotonic buffer (1.5 mM KCl, 2.5 mM MgCl2, and 5.0 mM Tris-Cl, pH 
7.4) and 200 μl hypotonic lysis buffer (same with 2% sodium deoxycho-
late, 2% Triton X-100, and 2.5 mM DTT) plus CHX and gently disrupted 
using a Dounce homogenizer. The lysates were centrifuged at 8,000 g 
for 10 minutes at 4°C. The supernatant was supplemented with 80 μl 
heparin. Linear 10% to 45% sucrose gradients (80 mM NaCl, 5 mM 
MgCl2, 20 mM Tris-Cl, pH 7.4, and 1 mM DTT) were formed manually. 
Gradients were centrifuged at 230,000 g for 3 hours at 4°C and separated 
through a live OD 254 nm ultraviolet spectrometer. All experiments 
were repeated at least 3 times under the same conditions.
Protein samples from all fractions were isolated and Western blot 
was performed for RPS3 or RPS6 and RPL11 present in the 40S and 
60S subunits, respectively. Monosomes, both light and heavy polysome 
fractions, were determined as reported previously (53). TRIzol Reagent 
(Invitrogen) was added to each collected fraction, and RNA was isolated 
according to the manufacturer’s protocol. Reverse transcription and 
RT-PCR were performed as mentioned previously. 18S rRNA primers 
were used for normalization of abundance of the mRNA of interest in 
Figure 10. RNH1 is present in ribosomal fraction and binds to small ribosomal subunit. (A) Western blot analysis 
of RNH1 and RPs in polysome-enriched pellet (P100) and the postpolysomal supernatant (S100) fraction prepared 
from K562 cytoplasmic extracts. Blots are representative of 3 independent experiments. (B) Western blot analysis 
of the distribution of RNH1 and RPs in sucrose gradient polysome profile fractions prepared from K562 cell lysates. 
Blots are representative of 3 independent experiments. (C) Polysome-enriched fractions were treated with high salt 
(0.5 M KCl). Distribution of RNH1 and RPs was analyzed by Western blot in sucrose gradient polysome profiles. Blots 
are representative of 3 independent experiments. (D) Polysome-enriched fractions were dissociated to 40S and 60S 
ribosomal subunits with puromycin. The distribution of RNH1 and RPs in pooled fractions was analyzed by Western 
blot in sucrose gradient polysome profiles. Blots are representative of 3 independent experiments. 18S and 28S rRNA 
from pooled 40S and 60S fractions were analyzed to check the purity of the 40S and 60S subunits, respectively.
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Immunoprecipitation and MS analyses. Stable mock construct– and 
Flag-RNH1–expressing K562 cells were resuspended in lysis buffer 
(20 mM Tris, pH 7.4, 150 mM NaCl, 1% [vol/vol] Nonidet-P40, 10 
mM EDTA). In other experiments, Flag- or VSV-tagged constructs and 
empty vector, as shown in Supplemental Figure 10A, were transfected 
into HEK293T cells by the calcium-phosphate method. At 24 hours 
after transfection, cells were resuspended in lysis buffer as mentioned 
above. Extracts were immunoprecipitated with anti-Flag or anti-VSV 
agarose beads and then were assessed by immunoblot. For MS anal-
yses, beads after immunoprecipitation were washed with PBS and 
resuspended in 1× SDS gel-loading buffer to extract bound proteins. 
Samples were resolved on a 10% mini-polyacrylamide gel for about 2 
cm, fixed, and rapidly stained with Coomassie blue. Entire gel lanes 
and used to infect K562 cells. To establish stable cell lines, K562 cells 
were selected with puromycin (5 μg ml−1) 3 days after infection.
GATA1 rescue experiments. GATA1 expression plasmid was gener-
ated as described previously (6). The empty HMD and HMD-GATA1 
vectors were transfected with lipofectamine (Invitrogen) in RNH1-KO 
K562 cells and infected with lentivirus vectors in E9.5 Rnh1-deficient 
mouse yolk sac cells. At 48 hours after transfection or after infection, 
transfection or transduction efficiency was monitored by GFP expres-
sion (both vectors contain GFP). GFP-positive cells were enriched by 
FACS sorting and used to perform benzidine staining and Western 
blot with K562 cells. In the case of yolk sac cells, GFP-positive cells 
were cultured for 7 days in methyl cellulose medium, which supports 
erythroid differentiation.
Figure 11. RNH1 binds to RPs. (A) Functional enrichment analysis of RNH1-binding proteins 
identified by MS (Benjamini-Hochberg adjusted P values < 0.05). Protein interaction networks 
were visualized using Osprey. (B) Whole cell lysates of stable K562 cells expressing mock or 
Flag-RNH1 vectors (left) were used for anti-Flag immunoprecipitation and immunoblotting, 
as indicated (right). Blots are representative of 3 independent experiments.
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ufacturer’s instructions. The immunoprecipitate was washed once with 
lysis buffer; then bound proteins were eluted in SDS sample buffer (3×) 
by heating at 70°C for 10 minutes. Western blot was performed using 
antibodies against GATA1 or TAMRA (MA1-041, Invitrogen)
Lentiviral production. Lentiviral shRNA plasmids against RNH1 
were purchased from MilliporeSigma. Lentiviruses for shRNA 
were produced by cotransfecting HEK293T cells with the shRNA- 
containing plasmid targeting RNH1 or scramble (pLKO.1 
plasmids: shRNH1, 5′-CCGGGCTGGTCCTGTACGACATTTACTC-
GAGTAAATGTCGTACAGGACCAGCTTTTTG-3′; 5′; shScramble, 5′- 
C C G G C A A C A A G AT G A A G A G C A C C A A C T C G A G T T G G T-
GCTCTTCATCTTGTTGTTTTT-3′) plus a lentiviral packaging sys-
tem (pMD2 VSV and pCMV DR8.91). Cells were transfected using 
Lipofectamine 2000 transfection reagent (Invitrogen). Supernatant 
was collected at 72 hours after transfection and filtered with a 0.45 
mm filter to clear cell debris. 30 ml of virus containing supernatant 
was collected and passed through a Whatman Puradisc 45 μm filter 
(GE Healthcare Life Sciences, catalog 6780-2504). After addition of 
7.5 ml PBS, 1.3 ml of 5 M NaCl, and 8 ml PEG 8000 solution, the mix-
ture was incubated at 4°C on a rotation wheel overnight. PEG 8000 
solution was prepared by dissolving 200 g polyethylene glycol 8000 
(Carl Roth, catalog 0263) in 200 ml of PBS, followed by autoclave 
treatment. The virus was precipitated the next day by centrifugation at 
3,220 g at 4°C for 1 hour. The virus-containing pellet was resuspended 
in PBS and stored at –80°C until use.
Isolation of primary human CD34+ HSPCs. Primary human CD34+ 
HSPCs were isolated from G-CSF–mobilized peripheral blood using 
the CD34 MicroBead Kit (Miltenyi Biotec, catalog 130-046-702) 
according to the manufacturer’s protocol. Purity was assessed by flow 
cytometry using a PE-conjugated anti-human CD34 antibody (Miltenyi 
Biotec, catalog 130-098-140) and was at least 94%.
Expansion and lentiviral infection of primary human CD34+ HSPCs. 
After isolation, primary human CD34+ HSPCs were expanded in 
StemSpan SFEM (Stemcell Technologies, catalog 09600) supple-
mented with StemSpan CC100 (Stemcell Technologies, catalog 
02690) for 5 days (expansion phase). Lentiviral infection was started 
on day 2 of the expansion phase and continued for a total of 12 hours. 
For this purpose, cells were cultured at a density of 106 cells/ml. Con-
were excised into 5 equal regions from top to bottom and digested 
with sequencing-grade trypsin (Promega) as described (55). Data- 
dependent liquid chromatography–tandem MS (LC-MS/MS) analysis of 
extracted peptide mixtures after digestion was carried out on a hybrid 
linear trap LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Sci-
entific) interfaced via a nanoelectrospray source to a Dionex 3000 RSLC 
nanoflow UHPLC. Peptides were separated on a Dionex Pepmap C18 (75 
μm ID × 250 mm, 2 μm) capillary column (Dionex) along a 90-minute 
gradient from 5% to 85% acetonitrile in 0.1% formic acid at a flow rate 
of 200 nl/minutes. Raw data were used to query a nonredundant protein 
database using MASCOT software (Matrix Science; version 2.4). Func-
tional enrichment analysis was conducted using DAVID bioinformatics 
tools (http://david.abcc.ncifcrf.gov/) (56, 57). Protein interaction net-
works were visualized using Osprey (58). For immune blot, the follow-
ing antibodies were used: RNH1 (catalog H00006050-D01P, Abnova), 
RPS3 (catalog sc-135390, Santa Cruz Biotechnology Inc.), RPL11 (catalog 
sc-25931, Santa Cruz Biotechnology Inc.), RPS6 (catalog 2317, Cell Signal-
ing Technology), EEF2 (catalog 2332, Cell Signaling Technology), β-actin 
(catalog ab8227, Abcam), and Flag-Ab (catalog F1804 Sigma-Aldrich).
Protein labeling and immunoprecipitation coupled to Click-iT reaction. 
Click-iT reaction was performed as described previously (6). Briefly, 
WT and RNH1-KO K562 cells were washed with warm PBS and incu-
bated in methionine-free RPMI medium (R7513, Sigma-Aldrich) with 
10% FBS and 2 mM l-glutamine for 1 hour at 37°C, 5% CO2, to deplete 
methionine reserves. For labeling, Click-iT AHA (l-azidohomoalanine, 
C10102, Life Technologies) was added at a final concentration of 50 μM 
for 4 hours at 37°C, 5% CO2. Cells were washed twice in cold PBS and 
resuspended in lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1% [vol/
vol] Nonidet-P40, 10 mM EDTA) supplemented with protease inhibitor 
cocktail (S8820, Sigma-Aldrich). Cell lysates were prepared by incuba-
tion for 30 minutes on ice and centrifugation at 16,000 g for 10 minutes 
at 4°C to remove cellular debris. Using these whole cell lysates, immuno-
precipitation was performed with GATA1 antibody (catalog 4591, Cell 
Signaling Technology) bound to Dynabeads Protein G (10003D, Life 
Technologies) for 3 hours with rotation at 4°C. The antibody-antigen 
complex was washed 3 times with lysis buffer, and the Click-iT reaction 
was performed using TAMRA alkyne and the Click-iT Protein Reaction 
Buffer Kit (C10276, Invitrogen) for 1 hour at 4°C according to the man-
Figure 12. RNH1 is a ribosomal- 
associated protein that regulates 
erythropoiesis by controlling GATA1 
translation. RNH1 is a ribosomal- 
associated protein involved in transla-
tion of GATA1, which leads to efficient 
differentiation of progenitor cells to 
mature erythroid cells. Lack of RNH1 
decreases GATA1 levels, which leads to 
an arrest in differentiation.
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rization (BE39/16). Mice were handled according to Swiss Federal 
Veterinary Office guidelines under valid authorization. Approval for 
the use of human CD34+ cells was obtained from the Kantonale Ethik-
kommission (Bern, Switzerland).
Data availability. All data sets generated and analyzed during the 
current study are available in Supplemental Tables 1–5. Microarray 
and RNA-seq data that support the findings of the study were depos-
ited in the NCBI’s gene expression omnibus (GEO GSE48146). RNA-
seq data are available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress, E-MTAB-5162).
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centrated virus was added at a ratio of 1:20 and polybrene (Santa Cruz 
Biotechnology Inc., catalog sc-134220) at a concentration of 8 μg/ml. 
Selection was carried out for 30 hours after washing by the addition of 
1 μg/ml puromycin (Sigma-Aldrich, catalog P9620). After the expan-
sion phase, cells were counted and split into 2 portions. One portion 
was used for in vitro erythroid differentiation and the other one for in 
vitro neutrophilic differentiation.
In vitro erythroid differentiation. In vitro erythroid differenti-
ation was adapted from a previously published protocol (59). In 
phase 1 (days 0–6), cells were cultured at a density of 105–106 cells/
ml in IMDM (Gibco, Thermo Fisher Scientific; catalog 21980-032) 
supplemented with 3% human AB serum and 2% human AB plasma 
(Interregional Blood Transfusion SRC), 1% penicillin/streptomycin 
(Gibco, Thermo Fisher Scientific; 15070-063), 3 IU/ml heparin (Sigma- 
Aldrich, catalog H3149), 200 μg/ml holo-transferrin (Sigma-Aldrich, 
catalog T0665), 10 μg/ml insulin (Sigma-Aldrich, catalog I3536), 1 IU/
ml erythropoietin (PeproTech, catalog 100-64), 10 ng/ml stem cell 
factor (PeproTech, catalog 300-07), and 1 ng/ml IL-3 (PeproTech, 
catalog 200-03). In phase 2 (day 6–12), IL-3 was omitted.
In vitro neutrophilic differentiation. In vitro neutrophilic differenti-
ation was adapted from a previously published protocol (60). In phase 
1 (days 0–3), cells were cultured at a density of 105–106 cells/ml in 
IMDM (Gibco, Thermo Fisher Scientific; catalog 21980-032) supple-
mented with 10% FCS (Amimed, catalog 2-01F10-I), 1% penicillin/
streptomycin (Gibco, Thermo Fisher Scientific; 15070-063), 100 ng/
ml stem cell factor (PeproTech, catalog 300-07), and 100 ng/ml IL-3 
(PeproTech, catalog 200-03). In phase 2 (days 3–12), G-CSF (Pepro-
Tech, catalog 300-23) was also supplemented.
May-Grünwald-Giemsa staining. Cells (50,000) were resuspended 
in 200 μl culture medium and spun onto a slide in a Cytospin 4 Cyto-
centrifuge (Thermo Scientific, catalog A78300003) at 40 g for 10 
minutes. Slides were air-dried for at least 10 minutes. Slides were then 
stained in May-Grünwald solution (Merck, catalog 1.01424.2500) for 
4 minutes, rinsed in deionized water for 2 minutes, stained in Giemsa 
solution (Merck, catalog 1.09204.0500) for 14 minutes, and rinsed 
twice in deionized water for 2 minutes and 1 minute, respectively. 
Photographs were taken with a PMW-10MD camera from Sony using 
a Carl Zeiss, Axioskop 50 microscope
Statistics. Data are expressed as mean ± SEM or mean ± SD of at least 
3 biological replicates. Comparison between 2 groups was performed by 
2-tailed t test. A value of P < 0.05 was considered to be statistically signif-
icant. All statistical analyses were calculated using GraphPad Prism. No 
statistical methods were used to predetermine sample size. The exper-
iments were not randomized, and the investigators were not blinded to 
allocation during experiments and outcome assessment. Gene expres-
sion studies were performed using 3 independent biological replicates 
from each genotype (Rnh1+/+, Rnh1+/–, and Rnh1–/–). RNA-seq experiments 
were also performed in triplicate. MS studies were performed once.
Study approval. All animal experiments were approved by the 
Swiss Federal Veterinary Office (Bern, Switzerland) under valid autho-
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